Skip to Main Content
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Cody Pietras

Director 3; Executive Director, Yale Cardiovascular Research Group

Contact Information

Cody Pietras
Yale Cardiovascular Clinical Research

Coauthors

Selected Publications

  • Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER IIIGarot P, Leon M, Saito S, Baumbach A, Kereiakes D, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, McLaurin B, Cequier A, Hofma S, Dib N, Namiki A, Takahashi A, Kakuta T, Hirohata A, Lansky A. Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 100515. DOI: 10.1016/j.jscai.2022.100515.
  • Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset AnalysisLansky AJ, Tirziu D, Moses JW, Pietras C, Ohman EM, O'Neill WW, Ekono MM, Grines CL, Parise H. Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis The American Journal Of Cardiology 2022, 185: 29-36. PMID: 36210212, DOI: 10.1016/j.amjcard.2022.08.032.
  • TCT-209 Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Patients With Diabetes Mellitus: Results of the Randomized Chocolate Touch StudyParikh S, Zeller T, Shishehbor M, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Kashyap V, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi K, Wali A, Lansky A. TCT-209 Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Patients With Diabetes Mellitus: Results of the Randomized Chocolate Touch Study Journal Of The American College Of Cardiology 2022, 80: b84. DOI: 10.1016/j.jacc.2022.08.246.
  • Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study) Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.
  • Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes MellitusThomas A, Kereiakes D, Baumbach A, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Cequier Á, Takahashi A, Cannon L, Amoroso G, Kakuta T, Saito S, Leon M, Lansky A. Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100033. DOI: 10.1016/j.jscai.2022.100033.
  • CLINICAL PREDICTORS OF EMBOLIC BURDEN AFTER TAVR: AN ANALYSIS OF THE SAFEPASS 2 CLINICAL STUDYLansky A, White J, Stewart J, Blake J, Smyth D, Pasupati S, Nair R, Parise H, Pietras C, Webster M, Kawakami R, Virmani R, Leipsic J. CLINICAL PREDICTORS OF EMBOLIC BURDEN AFTER TAVR: AN ANALYSIS OF THE SAFEPASS 2 CLINICAL STUDY Journal Of The American College Of Cardiology 2022, 79: 628. DOI: 10.1016/s0735-1097(22)01619-9.
  • Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III SubstudyPatel K, Lansky A, Kereiakes D, Windecker S, Cristea E, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Brogno D, Janssens L, Vrolix M, Gómez-Blázquez I, Sahul Z, Kabour A, Salido L, Cleman M, Saito S, Leon M, Baumbach A, Investigators I. Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100004. DOI: 10.1016/j.jscai.2021.100004.
  • TCT-290 Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus: Results From the PIONEER III Clinical TrialThomas A, Kereiakes D, Leon M, Baumbach A, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, Mclaurin B, Cequier A, Takahashi A, Amoroso G, Kakuta T, Carney R, Saito S, Lansky A. TCT-290 Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus: Results From the PIONEER III Clinical Trial Journal Of The American College Of Cardiology 2021, 78: b119. DOI: 10.1016/j.jacc.2021.09.1143.
  • TCT-316 Impact of Geographic Variation on the Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent: Results From the PIONEER III Clinical Trial in North America, Europe, and JapanGarot P, Leon M, Saito S, Baumbach A, Kereiakes D, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, Mclaurin B, Cequier A, Hofma S, Dib N, Takahashi A, Kakuta T, Hirohata A, Lansky A. TCT-316 Impact of Geographic Variation on the Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent: Results From the PIONEER III Clinical Trial in North America, Europe, and Japan Journal Of The American College Of Cardiology 2021, 78: b129-b130. DOI: 10.1016/j.jacc.2021.09.1169.
  • TCT-118 Propensity-Adjusted Population-Based Analysis of Impella in Patients Undergoing High-Risk PCI From a Large-Scale Claims DatasetLansky A, Tirziu D, Pietras C, Moses J, Ohman E, O'Neill W, Grines C, Needham K, Ekono M, Gregory D, Parise H. TCT-118 Propensity-Adjusted Population-Based Analysis of Impella in Patients Undergoing High-Risk PCI From a Large-Scale Claims Dataset Journal Of The American College Of Cardiology 2021, 78: b49-b50. DOI: 10.1016/j.jacc.2021.09.968.
  • SIMILAR OUTCOMES WITH THE SUPREME™BIODEGRADABLE DRUG COATED CORONARY STENT SYSTEM IN ACUTE CORONARY SYNDROME AND CHRONIC CORONARY SYNDROMES: RESULTS OF THE PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED PIONEER III TRIALLansky A, Saito S, Curtis M, Kereiakes D, Baumbach A, Bertolet B, Zidar J, McLaurin B, Dib N, Smits P, Diaz V, Cequier A, Hofma S, Pietras C, Windecker S, Leon M. SIMILAR OUTCOMES WITH THE SUPREME™BIODEGRADABLE DRUG COATED CORONARY STENT SYSTEM IN ACUTE CORONARY SYNDROME AND CHRONIC CORONARY SYNDROMES: RESULTS OF THE PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED PIONEER III TRIAL Journal Of The American College Of Cardiology 2021, 77: 1211. DOI: 10.1016/s0735-1097(21)02570-5.
  • Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical TrialLansky AJ, Kereiakes DJ, Baumbach A, Windecker S, Hussain Y, Pietras C, Dressler O, Issever O, Curtis M, Bertolet B, Zidar JP, Smits PC, Díaz V, McLaurin B, Hofma S, Cequier Á, Dib N, Benit E, Mathur A, Brogno D, Berland J, Wykrzykowska J, Piegari G, Brugaletta S, Saito S, Leon MB, Investigators O. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial Circulation 2021, 143: 2143-2154. PMID: 33820424, DOI: 10.1161/circulationaha.120.052482.
  • Refining drug-eluting stent technologies: from engineering to basic scienceLansky A, Chun H, Pietras C, Hussain Y. Refining drug-eluting stent technologies: from engineering to basic science European Heart Journal 2021, 42: 1770-1772. PMID: 33624813, DOI: 10.1093/eurheartj/ehab091.
  • Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination.Lansky A, Shah T, Wijns W, Stefanini GG, Farb A, Kaplan A, Xu B, Pietras C, Velazquez E, Serruys PW, Mahfoud F, Baumbach A. Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination. EuroIntervention 2020, 16: 787-793. PMID: 33215993, DOI: 10.4244/eijv16i10a147.
  • Cerebral Embolic Protection Burden of Proof ∗Lansky A, Pietras C, Shah T. Cerebral Embolic Protection Burden of Proof ∗ JACC Cardiovascular Interventions 2020, 13: 2156-2158. PMID: 32972579, DOI: 10.1016/j.jcin.2020.06.030.
  • TCT-365 Contemporary Outcomes in No-Option Chronic Critical Limb Ischemia: A Systematic Review and Meta-AnalysisGhare M, Pietras C, Tirziu D, Tsay C, Parise H, White R, Lansky A. TCT-365 Contemporary Outcomes in No-Option Chronic Critical Limb Ischemia: A Systematic Review and Meta-Analysis Journal Of The American College Of Cardiology 2018, 72: b148. DOI: 10.1016/j.jacc.2018.08.1517.
  • TCT-85 Endovascular Repair of Penetrating Atherosclerotic Ulcers With the Cardiatis Multilayer Flow Modulator Implant as an Alternative to Covered Endografts to Preserve Branch Vessel PatencyTirziu D, White R, Gray W, Pietras C, Ghare M, Lansky A. TCT-85 Endovascular Repair of Penetrating Atherosclerotic Ulcers With the Cardiatis Multilayer Flow Modulator Implant as an Alternative to Covered Endografts to Preserve Branch Vessel Patency Journal Of The American College Of Cardiology 2018, 72: b38. DOI: 10.1016/j.jacc.2018.08.1180.
  • Carotid Disease and Stroke After Transcatheter Aortic Valve ReplacementLansky AJ, Ghare MI, Pietras C. Carotid Disease and Stroke After Transcatheter Aortic Valve Replacement Circulation Cardiovascular Interventions 2018, 11: e006826. PMID: 29895605, DOI: 10.1161/circinterventions.118.006826.
  • Proposed Standardized Neurological Endpoints for Cardiovascular Clinical TrialsAn Academic Research Consortium InitiativeLansky AJ, Messé SR, Brickman AM, Dwyer M, van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical TrialsAn Academic Research Consortium Initiative European Heart Journal 2017, 39: 1687-1697. PMID: 28171522, PMCID: PMC6251670, DOI: 10.1093/eurheartj/ehx037.
  • Abstract 125: Burden & Timing of Recurrent Angina in Patients With Incomplete Revascularization Following Percutaneous Coronary InterventionLansky A, Ng V, Cristea E, Bouras G, Pietras C, Pangilinan D, Polsonetti B, Herriott D, Barr P, Oppelt T. Abstract 125: Burden & Timing of Recurrent Angina in Patients With Incomplete Revascularization Following Percutaneous Coronary Intervention Circulation Cardiovascular Quality And Outcomes 2016, 9 DOI: 10.1161/circoutcomes.9.suppl_2.125.
  • The TriGuard embolic deflection device for prevention of stroke and cerebral embolization during transcatheter aortic valve replacementBaumbach A, Pietras C, Lansky A. The TriGuard embolic deflection device for prevention of stroke and cerebral embolization during transcatheter aortic valve replacement Expert Review Of Medical Devices 2015, 12: 649-651. PMID: 26364995, DOI: 10.1586/17434440.2015.1086642.
  • Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study.Baumbach A, Mullen M, Brickman AM, Aggarwal SK, Pietras CG, Forrest JK, Hildick-Smith D, Meller SM, Gambone L, den Heijer P, Margolis P, Voros S, Lansky AJ. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention 2015, 11: 75-84. PMID: 25868876, DOI: 10.4244/eijy15m04_01.
  • Local delivery of paclitaxel in the treatment of peripheral arterial diseaseNg VG, Mena C, Pietras C, Lansky AJ. Local delivery of paclitaxel in the treatment of peripheral arterial disease European Journal Of Clinical Investigation 2015, 45: 333-345. PMID: 25615282, DOI: 10.1111/eci.12407.
  • Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial) The American Journal Of Cardiology 2014, 114: 1638-1645. PMID: 25312637, DOI: 10.1016/j.amjcard.2014.09.003.
  • Fractional Flow Reserve From 3-Dimensional Quantitative Coronary Angiography Fresh Light Through an Old Window∗Lansky AJ, Pietras C. Fractional Flow Reserve From 3-Dimensional Quantitative Coronary Angiography Fresh Light Through an Old Window∗ JACC Cardiovascular Interventions 2014, 7: 778-780. PMID: 25060021, DOI: 10.1016/j.jcin.2014.05.002.
  • Optimal Angiographic Technique and Quantitative AnalysisLansky A, Pietras C, Haleem K, Ng V. Optimal Angiographic Technique and Quantitative Analysis 2013, 9-22. DOI: 10.1007/978-1-4471-4528-8_2.
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trialLansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial Catheterization And Cardiovascular Interventions 2008, 72: 917-924. PMID: 19016469, DOI: 10.1002/ccd.21714.
  • Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials)Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Müller R, Störger H, Hauptmann KE, Grube E. Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials) The American Journal Of Cardiology 2006, 98: 464-469. PMID: 16893698, DOI: 10.1016/j.amjcard.2006.02.054.
  • Treatment of Coronary Artery Perforations Complicating Percutaneous Coronary Intervention With a Polytetrafluoroethylene-Covered Stent GraftLansky AJ, Yang YM, Khan Y, Costa RA, Pietras C, Tsuchiya Y, Cristea E, Collins M, Mehran R, Dangas GD, Moses JW, Leon MB, Stone GW. Treatment of Coronary Artery Perforations Complicating Percutaneous Coronary Intervention With a Polytetrafluoroethylene-Covered Stent Graft The American Journal Of Cardiology 2006, 98: 370-374. PMID: 16860026, DOI: 10.1016/j.amjcard.2006.02.041.
  • Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial InfarctionLansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction Circulation 2005, 111: 1611-1618. PMID: 15811868, DOI: 10.1161/01.cir.0000160362.55803.40.
  • Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in WomenLansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, New G, Grines CL, Pietras CG, Kern MJ, Ferrell M, Leon MB, Mehran R, White C, Mieres JH, Moses JW, Stone GW, Jacobs AK. Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women Circulation 2005, 111: 940-953. PMID: 15687113, DOI: 10.1161/01.cir.0000155337.50423.c9.
  • 3. Lansky AJ, Pietras C. Special Subsets: Women. In: Kern MJ, Berger PB, eds. SCAI Interventional Cardiology Board Review Book. Philadelphia, PA: Lippincott Williams & Wilkins;2006:203-214.3. Lansky AJ, Pietras C. Special Subsets: Women. In: Kern MJ, Berger PB, eds. SCAI Interventional Cardiology Board Review Book. Philadelphia, PA: Lippincott Williams & Wilkins;2006:203-214.
  • 2. Lansky AJ, Pietras C, Corral M, Lazar D, Jankovic J. Core laboratories: a crucial component of clinical research. CCHeart Review. 2011;3:8-152. Lansky AJ, Pietras C, Corral M, Lazar D, Jankovic J. Core laboratories: a crucial component of clinical research. CCHeart Review. 2011;3:8-15
  • 1. Lansky AJ, Pietras C, Kamran H, Ng V. Optimal Angiographic Technique and Quantitative Analysis. In: Thompson C. (Ed.) Textbook of Cardiovascular Interventions. New York, NY: Springer Press, 2011.1. Lansky AJ, Pietras C, Kamran H, Ng V. Optimal Angiographic Technique and Quantitative Analysis. In: Thompson C. (Ed.) Textbook of Cardiovascular Interventions. New York, NY: Springer Press, 2011.
Edit Profile